It mimics two natural incretin hormones, making it distinct from single GLP-1 agonists like semaglutide
Microdosing GLP-1/GIP therapies may help: Improve glycemic control, stable blood glucose levels, and blood pressure support Reduction in visceral fat and waist circumference Potential improvements in lipid profiles Reduce systemic inflammation markers associated with cardiometabolic disease Glycine amino acid that supports protein synthesis, endothelial function, and insulin sensitivity Reduce cardiovascular risk factors such as insulin resistance and central adiposity Whats Included Monthly compounded tirzepatide + glycine (Up to 3mg/week) or 2ml tirzepatide with B12 every 2 months with labs Personalized microdosing protocol Ongoing provider oversight with labs every six months This is not an FDA-approved microdosing regimen
Pyke C, Heller RS, Kirk RK, rskov C, Reedtz-Runge S, Kaastrup P, et al
Microdosing GLP-1 means using semaglutide or tirzepatide at doses significantly below the standard therapeutic targets
His BMI is approximately 28
